|
|
||||||||
Eur J Cardiothorac Surg 2007;31:806-811. doi:10.1016/j.ejcts.2007.01.045
Copyright © 2007, European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved
a Division of Thoracic Surgery, University Hospital, CH-8091 Zurich, Switzerland
b Division of Oncology, University Hospital, CH-8091 Zurich, Switzerland
c Institute of Polymer Research, Swiss Federal Institute of Technology (ETHZ), CH-8093 Zurich, Switzerland
d Shanghai Chest Hospital, Medical Centre of Fudan University
Received 5 November 2006; received in revised form 15 January 2007; accepted 22 January 2007.
* Corresponding author. Address: Clinic of Thoracic Surgery, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland. Tel.: +41 1 255 34 16; fax: +41 1 255 88 05. (Email: tqiang{at}hotmail.com).
Objective: To test the effects of a continuous medium flow inside DegraPol® scaffolds on the reepithelialization and revascularization processes of a tissue-engineered trachea prosthesis. Methods: In this proof-of-principle study a continuous medium flow was maintained within a tubular DegraPol® scaffold by an inserted porous catheter connected to a pump system. The impact of the intra-scaffold medium flow on the survival of a tracheal epithelial sheet wrapped around and on chondrocyte delivery to the DegraPol® scaffold was studied. In the chick embryo, chorioallantoic membrane (CAM) model angiogenesis within the biomaterial was investigated. Results: Scanning electronic microscopy (SEM) images showed an intact epithelial layer after a 2-week support by continuous medium flow underneath. On histology, three-dimensional cell growth was detected in the continuous delivery group. The CAM assay showed that angiogenesis was enhanced within the DegraPol® scaffolds when vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was added to the perfusate. Conclusions: Taken together, these results demonstrated that the built-in perfusion system within DegraPol® scaffolds was able to maintain an intact tracheal epithelial layer, allowed a continuous delivery of cells, and kept an efficient VEGF/VPF expression level which accelerated angiogenic response in the CAM assay. This design combines the in vitro and in vivo parts of tissue engineering and offers the possibility to be used as an in vivo bioreactor implanted for the tissue-engineered reconstruction of trachea and of other organs.
Key Words: Tissue engineering Tracheal prosthesis Reepithelialization Revascularization Bioreactor
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |